12.03.25 -- CMC Challenges In The Development Of Conjugated LNP Platforms

Our findings provide critical insights into refining ASO extraction protocols, which can enhance the accuracy of downstream analyses and support further research into ASO-based therapeutics.

Explore the critical factors in scaling up lipid nanoparticle (LNP) formulation, comparing the advantages and limitations of both laminar (microfluidic) and turbulent (tee and jet) mixing technologies.

Delve into the intricacies of riboswitch behavior and ligand interactions and gain valuable insights into gene regulation and potential therapeutic targets.

By directing radioactive isotopes straight to diseased tissue, these agents deliver potent, localized treatment while sparing healthy cells, a major leap forward for patients with treatment-resistant cancers.

Accelerate essential process development activities with instrumentation solution allowing for highly reproducible and scalable production of RNA-LNPs.

Here, two distinct polishing processes using monoliths are compared: bind-elute (BE) and the more recently developed sample displacement purification (SDP).

RNA offers exciting potential for vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing persist.

Explore a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.

The rapid scale-up of mRNA drug manufacturing exposes supply chain vulnerabilities for key ingredients like lipids. Resilience is now critical.

Explore the automated production of protein microparticles using an innovative method that offers a standardized and scalable solution for co-precipitation in biopolymer particle fabrication.

Jubilant HollisterStier partnered with SCC to launch a biomanufacturing program, building career pathways for Spokane’s growing life sciences and pharmaceutical manufacturing sector.